Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2007

Cisbio Strengthens HTRF Portfolio with Lumiphore’s Fluorescent Lanthanide Detection Reagents

  • Lumiphore (www.lumiphore.com) will incorporate its Lumi4™ complexes into Cisbio (www.htrf.com) assays, under an exclusive partnership. Lumi4 complexes are a class of fluorescent lanthanide detection reagents. They reportedly have long emission lifetimes and higher signal-to-noise ratio than existing fluorophores. The technology will be applied to Cisbio’s current and future R&D initiatives in TR-FRET-based (time-resolved fluorescence resonance energy transfer) assays for drug discovery. Lumi4 compounds brings good photophysical properties, increased sensitivity, and stability to TR-FRET assays for high-throughput screening, according to Cisbio. The incorporation of these compounds into Cisbio’s HTRF® technology reportedly could enable a second generation of assay platforms, particularly in the fields of GPCR and kinase screening.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »